Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PYX-201 plus pembrolizumab in advanced solid tumors
2025-521828-30-00Phase 2Authorised
- Sponsor
- Pyxis Oncology
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, single-arm trial of micvotabart pelidotin and pembrolizumab in Nonhematologic neoplasms, sponsored by Pyxis Oncology. Planned start Jan 2026; status: authorised.
02
Drugs
micvotabart pelidotinpembrolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2025-521828-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521828-30-00.